Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 improves survival and tumor control in CLL mouse model

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. National incidence and survival of patients with non-invasive papillary urothelial carcinoma: a Danish population study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Moving treatment of Ta low grade bladder tumors from the operating theatre to the outpatient depart-ment

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  • Kim E M van Kessel
  • Kirstin A van der Keur
  • Lars Dyrskjøt
  • Ferran Algaba
  • Naeromy Y C Welvaart
  • Willemien Beukers
  • Ulrika Segersten
  • Bastian Keck
  • Tobias Maurer
  • Tatjana Simic
  • Marcus Horstmann
  • Marc-Oliver Grimm
  • Gregers G Hermann
  • Karin Mogensen
  • Arndt Hartmann
  • Niels Harving
  • Astrid C Petersen
  • Jørgen B Jensen
  • Kerstin Junker
  • Joost L Boormans
  • Francisco X Real
  • Núria Malats
  • Per-Uno Malmström
  • Torben F Ørntoft
  • Ellen C Zwarthoff
View graph of relations

Purpose: The European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC) recommend risk stratification based on clinicopathologic parameters. Our aim was to investigate the added value of biomarkers to improve risk stratification of NMIBC.Experimental Design: We prospectively included 1,239 patients in follow-up for NMIBC in six European countries. Fresh-frozen tumor samples were analyzed for GATA2, TBX2, TBX3, and ZIC4 methylation and FGFR3, TERT, PIK3CA, and RAS mutation status. Cox regression analyses identified markers that were significantly associated with progression to muscle-invasive disease. The progression incidence rate (PIR = rate of progression per 100 patient-years) was calculated for subgroups.Results: In our cohort, 276 patients had a low, 273 an intermediate, and 555 a high risk of tumor progression based on the EAU NMIBC guideline. Fifty-seven patients (4.6%) progressed to muscle-invasive disease. The limited number of progressors in this large cohort compared with older studies is likely due to improved treatment in the past two decades. Overall, wild-type FGFR3 and methylation of GATA2 and TBX3 were significantly associated with progression (HR = 0.34, 2.53, and 2.64, respectively). The PIR for EAU high-risk patients was 4.25. On the basis of FGFR3 mutation status and methylation of GATA2, this cohort could be reclassified into a good class (PIR = 0.86, 26.2% of patients), a moderate class (PIR = 4.32, 49.7%), and a poor class (PIR = 7.66, 24.0%).Conclusions: We conclude that the addition of selected biomarkers to the EAU risk stratification increases its accuracy and identifies a subset of NMIBC patients with a very high risk of progression. Clin Cancer Res; 24(7); 1586-93. ©2018 AACR.

Original languageEnglish
JournalClinical Cancer Research
Issue number7
Pages (from-to)1586-1593
Number of pages8
Publication statusPublished - 1 Apr 2018

ID: 54774577